Replies to post #5192 on Biotech Values

[DewDiligence]

Re: Tarceva monotherapy trial begins in first-line NSCLC:

According to Colin Goddard’s comments on the OSIP CC, there are 30K patients in the U.S. alone who are well-suited for this first-line, chemo-free treatment regimen, where Tarceva might be used off-label. This is in addition to an unspecified number of patients who might be suited for "deferred" first-line Tarceva following a few cycles of chemo.